Masivet

Masivet

Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs. Masivet® is an effective, well-tolerated and proven treatment for dog MCT and was the first tyrosine kinase inhibitor registered in veterinary oncology when it was approved by the European Medicine Agency in 2008. AB Science celebrated in 2018 the 10th anniversary of the…

Overview

Masivet

AB Science is developing its lead compound masitinib in veterinary medicine.   Since 2008 in Europe and since 2010 in the USA, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® in Europe and Kinavet in the…